This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cigna Shares on the Couch: Time to Stay Strong or Walk Away Now?
by Zacks Equity Research
CI looks worth holding as Evernorth growth, expanding pharmacy services, cheap valuation and shareholder returns support its long-term outlook.
CVS Health Delivers MBR Improvement: Is More Progress in the Cards?
by Moumi Mondal
CVS posts a sharper MBR as PDR impacts ease and government business strengthens while maintaining a cautious full-year outlook.
Select Medical Down 5% Despite Q3 Earnings Beat on Patient Volumes
by Zacks Equity Research
SEM's Q3 earnings drop 11.5% year over year due to the rising cost of services, despite a revenue beat and raised 2025 EPS guidance.
CVS' Health Care Delivery Arm Likely to See Better Financial Results
by Moumi Mondal
CVS Health's scaled-back Oak Street expansion, clinic closures and tech investments aim to drive stronger Health Care Delivery results next year.
Cigna Q3 Earnings Beat Estimates on Evernorth Health Unit Strength
by Zacks Equity Research
CI's Q3 earnings and revenues beat estimates as Evernorth Health Services powers growth despite healthcare headwinds.
Cigna (CI) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Cigna (CI) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cigna (CI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of +1.69% and +3.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Does UnitedHealth Stock Have More Upside After Q3 Earnings?
by Shaun Pruitt
UnitedHealth Group's (UNH) stock hasn't received the post-earnings rally that investors may have hoped for, but the medical giant was able to provide subtle signs that its operations are stabilizing.
Centene Q3 Earnings Beat Estimates on Increasing Premium
by Zacks Equity Research
CNC's Q3 earnings beat estimates as strong premium growth and rising membership in PDP and Marketplace units offset higher medical costs.
Will Lower Premiums Affect Cigna's Q3 Earnings? Key Insights Here
by Zacks Equity Research
CI's Q3 results hinge on strong Evernorth growth and surging investment income, but lower premiums and rising costs may weigh on margins.